

YSK Laboratories

A DC granule solution for smaller tablets for all patients

YSK Laboratories is an R&D-focused manufacturer of Directly Compressed Granules (DC Granules). Its innovative technology reduces tablet size and minimizes excipients, while enhancing dissolution and freeing up capacities. By eliminating solvents and in-process testing, its products are free from organic volatile Impurities. DC Granules significantly reduce production steps and overall costs, thereby increasing production efficiencies, yields, and output within the pharmaceutical industry.

July 2023

Launched Sodium Valproate and Valproic Acid (66.7%) DC Granules

March 2023

Launched Fexofenadine (48%) DC Granules

January 2023

Launched Sustained Release Metformin (75% and 80%) DC Granules

Seed
stage

12
employees

<\$1m
revenue

Operational Location(s)
India

Majority Ownership
Yuvansh Khokhani

Main Offering:

Solvent free DC Granules, R&D and process development services

“With an R&D focus, YSK Laboratories looks to commercialise and streamline pharmaceutical production whilst improving administrative properties.”

Yuvansh Khokhani
Founder

Executive insight

What's your USP in one sentence?

Our innovative technology reduces tablet size and minimizes excipients, while improving yields, efficiencies, and reducing costs.

YSK Laboratories, then to now

Inspired by patient struggles with tablet size, Yuvansh Khokhani created a concept for compact yet effective medications. Assembling a team of scientists, YSK Laboratories was founded in 2021. Within a year, its DC Granules technology was validated, reducing tablet size and optimizing pharmaceutical production. This breakthrough resulted in the launch of its first product in January 2023, sustained release Metformin. With a strong pipeline ahead, YSK Laboratories aims to commercialise and expand its portfolio.

What's your vision for the future?

To empower patients of all ages worldwide with safer, smaller, and easily administered medications.